Streetbeat News

Products Services

F

GM

STLA

TM

TSLA

WKSP

Toyota Motor Corporation (TM) has raised its full-year fiscal outlook due to strong hybrid demand, despite a slowdown in EV demand in the U.S. Worksport Ltd (WKSP, WKSPW) is preparing for the alpha release of its COR portable battery system. Toyota's Q2 revenue grew 24% YoY to $75.7 billion, with operating profit expanding over 155% YoY to $9.5 billion. Toyota has also raised its annual profit guidance from 3 trillion yen to 4.5 trillion yen ($29.8 billion). Meanwhile, Ford (F), General Motors (GM), and Stellantis (STLA) have suffered from a UAW strike, with Tesla (TSLA) potentially benefiting from a slower EV rollout from these automakers.

Portfolio Pulse from Upwallstreet

November 02, 2023 | 5:14 pm

SPCE

Virgin Galactic Holdings, Inc. (NYSE:SPCE) has announced the successful completion of its sixth space mission in six months, and tenth overall. The mission, named 'Galactic 05', saw the company's spaceship converted into a suborbital lab for space-based scientific research for the second time. The company plans to use insights from the mission to enhance the research capabilities of its future Delta-class spaceships.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 5:10 pm

ALPN

Alpine Immune Sciences has presented the first clinical data of povetacicept in autoimmune glomerulonephritis at ASN Kidney Week, which has led to an increase in its share price.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 5:04 pm

SGEN

Seagen Inc. (NASDAQ:SGEN) announced that it will present new data for its drug ADCETRIS in combination with immunotherapy for Hodgkin lymphoma at the 2023 ASH Annual Meeting. The company will also unveil a novel CD30-directed antibody-drug conjugate, SGN-35C. The data will include 12- and 24-month progression free survival data for ADCETRIS and immunotherapy combination in early and advanced stage classical Hodgkin lymphoma. ADCETRIS is a proven foundation of care for certain CD30-expressing lymphomas with more than 120,000 patients treated globally across seven indications.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 5:01 pm

CZR

DKNG

FOX

FOXA

PDYPY

The Texas Rangers won the 2023 World Series, marking their first championship in franchise history. The victory resulted in significant payouts for bettors who backed the team at the start of the season. The games were broadcast on Fox Corp. owned Fox. Bettors who placed bets on FanDuel, a unit of Flutter Entertainment, and Caesars Entertainment Inc also saw significant returns. DraftKings Inc has released odds for the 2024 World Series.

Portfolio Pulse from Chris Katje

November 02, 2023 | 4:56 pm

ELDN

Eledon Pharmaceuticals announced results from its ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation. This news has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:41 pm

ACLX

Arcellx Inc (NASDAQ: ACLX) announced new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma. The data shows a 100% overall response rate (ORR) in all patients. The stock is trading higher by 17.30% at $40.35.

Portfolio Pulse from Vandana Singh

November 02, 2023 | 4:39 pm

PBLA

Panbela Therapeutics Inc's stock is trading higher following the publication of preclinical and clinical data from studies of CPP-1X in recent-onset type 1 diabetes. The data, published in Cell Reports Medicine, showed that CPP-1X may preserve β cell function and is a safe, oral treatment option. The company's shares are up 31.80% at $1.05.

Portfolio Pulse from Vandana Singh

November 02, 2023 | 4:36 pm

META

Meta Platforms is launching a new A/B testing tool for Reels that allows creators to test different captions and thumbnails on mobile devices. This move is aimed at enhancing user engagement and content creation on the platform.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:36 pm

SBFM

Sunshine Biopharma has terminated its research agreement with Jewish General Hospital following unfavorable lab results on testing of its anti-cancer drug, Adva-27a. The company has paused the IND-enabling studies of Adva-27a pending a review of the possibility of chemical modification of the compound.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 4:25 pm